Abrezekimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAbrezekimab
Drug Alias NameCDP-7766VR-942UCB-4144
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-IL13
TargetsInterleukin-13
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVectura LtdUcb
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUcb PharmaVectura Ltd
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A